Arrakis Therapeutics

Waltham, Massachusetts-based Arrakis Therapeutics is a biopharmaceutical company that discovers and develops oral small-molecule medicines designed to directly target RNA for the treatment of severe diseases such as cancer. The enterprise utilizes a proprietary technology platform to identify drug candidates that intercept messenger RNA, preventing the production of disease-causing proteins that are traditionally considered undruggable by conventional therapeutic methods. The organization operates through venture funding and strategic licensing agreements, securing a $190 million upfront payment from Roche in 2020 and a $75 million upfront payment from Amgen in 2022. Operating with an estimated 50 to 150 employees, the biotechnology company has raised over $113 million in venture capital funding from prominent institutional backers including GV, Pfizer, and Canaan Partners. Arrakis Therapeutics was founded in 2015 by Jennifer Petter, Alan Walts, Raj Parekh, and Henri Termeer.

Arrakis Therapeutics is not a technology company—it is a biopharmaceutical company developing a new class of medicines that directly target RNA.[1][2][3]

High-Level Overview

Arrakis Therapeutics pioneers the discovery and development of RNA-targeted small-molecule (rSM) medicines, a novel drug modality designed to treat diseases previously considered undruggable.[1][5] The company focuses on three primary therapeutic areas: neurology, oncology, and rare genetic disorders.[1] Rather than building software or digital tools, Arrakis develops oral medicines that bind directly to RNA structures to modify their biological function and treat disease.[3][4] The company's mission centers on extending small-molecule medicines into new realms of RNA biology, unlocking therapeutic potential for patients across multiple disease categories.[5]

Arrakis operates with a clear value proposition: it has developed proprietary scientific platforms—TRYST™ and PEARL-seq™—that enable the rational identification of tractable RNA targets and the design of drug molecules with specific attributes like oral bioavailability and blood-brain barrier transport, which are difficult to achieve with current RNA-targeted therapies.[1] The company is backed by leading life sciences investors and has established strategic partnerships with major pharmaceutical firms.[3]

Origin Story

Arrakis was founded in 2015 by Jennifer Petter, who serves as Chief Innovation Officer and Chief Scientific Officer.[3] The company emerged from a distinctive insight: while other companies had discovered RNA-targeting small molecules opportunistically, Arrakis was founded to purposefully and systematically discover this new class of drugs using bioinformatics tools and chemical biology approaches.[3]

In October 2016, Michael Gilman, a former Biogen executive, joined as CEO, bringing significant pharmaceutical industry experience to lead the organization.[3] Early validation came quickly: in 2017, Arrakis raised $38 million from venture capital firm Canaan Partners alongside investments from Celgene and Pfizer.[3] By April 2019, the company had secured $75 million in additional financing to advance its small-molecule drug development pipeline.[3]

Core Differentiators

• Proprietary Platform Technology: Arrakis has designed two scientific platforms—TRYST™ and PEARL-seq™—that enable systematic identification of RNA targets and rational drug design, moving beyond opportunistic discovery to purposeful engineering.[1][3]

• Focus on "Undruggable" Targets: The company specifically targets mRNA encoding therapeutically compelling but previously "undruggable" proteins, addressing a major gap in current medicine.[1]

• Oral Bioavailability & BBB Transport: Arrakis designs small molecules with attributes—oral bioavailability, blood-brain barrier penetration, and reduced dosing frequency—that are difficult to achieve with existing RNA-targeted therapies.[1]

• Experienced Scientific & Management Leadership: The company brings together leaders in RNA structure, chemistry, and biology alongside a management team with a proven track record of building transformative biopharmaceutical companies.[1]

Role in the Broader Biotech Landscape

Arrakis operates at the intersection of two major biotech trends: the growing recognition of RNA as a therapeutic target and the push to develop small-molecule drugs that can address genetic and molecular diseases previously considered intractable. The company was recognized as an "Endpoints 11" disruptive biotech company in 2017, reflecting its pioneering position in this emerging field.[4]

The timing has been favorable for RNA-targeted therapeutics, as scientific understanding of RNA structure has advanced significantly. Arrakis's approach differs from gene therapy and antisense oligonucleotide therapies by focusing on small molecules—a modality that offers potential advantages in terms of manufacturability, distribution, and patient accessibility.[1][4]

The company's partnerships underscore its influence: in April 2020, Arrakis signed a $190 million licensing agreement with Roche for exclusive rights to develop RNA-targeted drugs across multiple disease areas.[3] In January 2022, Amgen partnered with Arrakis, committing a $75 million upfront payment to develop oral drugs that target and degrade RNA, with additional milestone-based funding possible.[3] These partnerships validate Arrakis's platform and extend its reach into major pharmaceutical development and commercialization infrastructure.

Quick Take & Future Outlook

Arrakis stands at a critical inflection point. The company has moved from early-stage discovery into clinical development, with data presentations for programs like myotonic dystrophy type 1 demonstrating its capability to rationally design disease-modifying RNA-targeted small molecules.[2] With major pharma partnerships providing both capital and development expertise, Arrakis is positioned to advance multiple candidates through clinical trials over the coming years.

The broader opportunity is substantial: if Arrakis can successfully demonstrate clinical efficacy and safety for its rSM medicines, it could unlock hundreds of previously inaccessible biological targets and establish a new standard for treating genetic and RNA-driven diseases. The company's success will likely influence how the entire biopharmaceutical industry approaches RNA as a therapeutic modality, potentially shifting investment and R&D focus toward this emerging drug class.